High risk pts on NSAIDs need prophylaxis!! @bcryer https://t.co/NAnHtkTNvL

Endoscopy and Worry are indicated in the face of DYSPEPSIA and any of these: @BCryer https://t.co/6TabKhiLPO

Multiple Rx options to treat H. Pylori - Dr. Cryer recs regimens of 14ds; top line w/ bismuth is most recommended. (most effective is the one the patient will actualy take!) @BCryer https://t.co/f6836Ga1Fz

H. Pylori is usually acquired during childhood, remains dormant until activated years later. Is assoc w/ PUD and gastric cancer, not dyspepsia. Baylor Univ Grand Round By Dr. Byron Cryer @BCryer https://t.co/KXZfigVYX9

Mixed Long-term Effects of Calcium and Vitamin D in Postmenopausal Women https://t.co/u2cf5hmTAE https://t.co/A4kdwG6eRm

JAK-pot: 46913 Rx courses on JAKi, TNFi, other MOA. Rx D/Cs for AEs: - TNFi = JAKi (HR 1.0) - Other MOA > JAKi (HR 1.11) - TNFi < tofacitinib (0.81) - TNFi > baricitinib (1.15) - TNFi < JAKi; if >65yrs w/ CV risk (0.79) https://t.co/N5XnPjxAXO https://t.co/AnoKM7fzM7

What do you know about monogenic and polygenic autoinflammatory diseases? Join Drs Liebowitz and Mehta as they review the challenges of these conditions. https://t.co/EqJRXSzrEs https://t.co/z5yuHDXUZ3

Effective Treatments for Still's Disease A systematic review of pharmacological treatments for adult-onset Still disease (AOSD) supports the efficacy of tocilizumab (TCZ), anakinra (ANK), and canakinumab (CNK). https://t.co/Qi98OXyoLJ https://t.co/DCgXfs0Bot

Depression and RA Dr. Jack Cush reviews the news, journal reports and regulatory approvals from the past week. https://t.co/nJZD4D2ByC https://t.co/ET3Xp9cK62

Vaccinations NOT linked to SLE risk. 17 studies (45 million) w/ F/U up to 2 yrs. No signif SLE risk: - all vaccinations (OR=1.1; CI 0.86–1.5) - HBV vax (OR=2.11; 1.11-4) - HPV (OR=1.4; 0.88–2.3) - Flu (OR=0.96; 0.82–1.1) - COVID (OR=0.44; 0.18–1.2) https://t.co/YpxSYL97DM https://t.co/hsytm9UpDC

JAK inhibitors maybe an option in refractory Juvenile Dermatomyositis. Metanalysis of 26 reports (195 pts) JDM Rx w/ JAKi (median 5 rys); most Rx w/ tofacitinib (57%), ruxolitinib(27%), baricitinib (15%), w/ Improvement in 90%, 69%, 93%, respectively. https://t.co/acdlU13MfX https://t.co/fTFVvPz0EH